| IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study G Marcucci, K Maharry, YZ Wu, MD Radmacher, K Mrózek, D Margeson, ... Journal of clinical oncology 28 (14), 2348, 2010 | 951 | 2010 |
| miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts AM Eiring, JG Harb, P Neviani, C Garton, JJ Oaks, R Spizzo, S Liu, ... Cell 140 (5), 652-665, 2010 | 699 | 2010 |
| Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine W Blum, R Garzon, RB Klisovic, S Schwind, A Walker, S Geyer, S Liu, ... Proceedings of the National Academy of Sciences 107 (16), 7473-7478, 2010 | 589 | 2010 |
| Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia K Mrózek, G Marcucci, D Nicolet, KS Maharry, H Becker, SP Whitman, ... Journal of clinical oncology 30 (36), 4515, 2012 | 525 | 2012 |
| TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study KH Metzeler, K Maharry, MD Radmacher, K Mrózek, D Margeson, ... Journal of clinical oncology 29 (10), 1373, 2011 | 427 | 2011 |
| Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression … H Becker, G Marcucci, K Maharry, MD Radmacher, K Mrózek, ... Journal of clinical oncology 28 (4), 596, 2010 | 426 | 2010 |
| ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category KH Metzeler, H Becker, K Maharry, MD Radmacher, J Kohlschmidt, ... Blood, The Journal of the American Society of Hematology 118 (26), 6920-6929, 2011 | 347 | 2011 |
| Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia G Marcucci, KH Metzeler, S Schwind, H Becker, K Maharry, K Mrózek, ... Journal of clinical oncology 30 (7), 742, 2012 | 344 | 2012 |
| RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression … JH Mendler, K Maharry, MD Radmacher, K Mrózek, H Becker, ... Journal of clinical oncology 30 (25), 3109, 2012 | 335 | 2012 |
| Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia S Liu, LC Wu, J Pang, R Santhanam, S Schwind, YZ Wu, CJ Hickey, J Yu, ... Cancer cell 17 (4), 333-347, 2010 | 289 | 2010 |
| Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and … P Kraiczy, J Hellwage, C Skerka, H Becker, M Kirschfink, MM Simon, ... Journal of Biological Chemistry 279 (4), 2421-2429, 2004 | 278 | 2004 |
| FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with … SP Whitman, K Maharry, MD Radmacher, H Becker, K Mrózek, ... Blood, The Journal of the American Society of Hematology 116 (18), 3622-3626, 2010 | 268 | 2010 |
| Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study S Schwind, K Maharry, MD Radmacher, K Mrózek, KB Holland, ... Journal of clinical oncology 28 (36), 5257, 2010 | 228 | 2010 |
| Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients G Marcucci, KS Maharry, KH Metzeler, S Volinia, YZ Wu, K Mrózek, ... Journal of clinical oncology 31 (17), 2086, 2013 | 215 | 2013 |
| Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms A Prestipino, AJ Emhardt, K Aumann, D O’Sullivan, SP Gorantla, ... Science translational medicine 10 (429), eaam7729, 2018 | 205 | 2018 |
| Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score G Marcucci, P Yan, K Maharry, D Frankhouser, D Nicolet, KH Metzeler, ... Journal of Clinical Oncology 32 (6), 548, 2014 | 158 | 2014 |
| BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically … S Schwind, G Marcucci, K Maharry, MD Radmacher, K Mrózek, ... Blood, The Journal of the American Society of Hematology 116 (25), 5660-5669, 2010 | 142 | 2010 |
| Recurrent ETNK1 mutations in atypical chronic myeloid leukemia CB Gambacorti-Passerini, C Donadoni, A Parmiani, A Pirola, S Redaelli, ... Blood, The Journal of the American Society of Hematology 125 (3), 499-503, 2015 | 126 | 2015 |
| Dose escalation of lenalidomide in relapsed or refractory acute leukemias W Blum, RB Klisovic, H Becker, X Yang, DM Rozewski, MA Phelps, ... Journal of Clinical Oncology 28 (33), 4919-4925, 2010 | 116 | 2010 |
| Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation S Hamarsheh, L Osswald, BS Saller, S Unger, D De Feo, JM Vinnakota, ... Nature communications 11 (1), 1659, 2020 | 108 | 2020 |
